NCT06725264View on ClinicalTrials.gov

Tyrosine Kinase 2 (TYK2) for GA and CS

PHASE2WithdrawnINTERVENTIONAL

0

Timeline

Start Date

March 31, 2025

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions

SarcoidosisGranuloma Annulare

Interventions

DRUG

Deucravacitinib

6 mg twice daily

Trial Locations (1)

06519

YCCI/Church Street Research Unit (CSRU), New Haven

Sponsors

Collaborators (1)

Bristol-Myers Squibb

All Listed Sponsors

collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Yale University

OTHER

NCT06725264 - Tyrosine Kinase 2 (TYK2) for GA and CS | Biotech Hunter | Biotech Hunter